Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
TACE Combined with Targeted Immunotherapy: A Strategy for Liver Transplantation Conversion and Survival Benefits in Patients with BCLC Stage B/C HCC
Saved in:
| Published in: | Journal of Hepatocellular Carcinoma |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: TACE Combined with Targeted Immunotherapy: A Strategy for Liver Transplantation Conversion and Survival Benefits in Patients with BCLC Stage B/C HCC
- Efficacy and Safety of TACE-HAIC Combined with Molecular Targeted Therapy and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
- A Preoperative MRI-Based Score to Predict High-Risk Pathology and Stratify Adjuvant Therapy Benefit in BCLC 0/A Hepatocellular Carcinoma
- A Mouse in vivo Model Mimicking MASH-Related HCC Pathogenesis
- Histone Methylation: A Pivotal Epigenetic Driver of the Malignant Transformation of MASLD-HCC
- SR-HCC Score: A Novel Nomogram for Predicting Spontaneous Rupture in Hepatocellular Carcinoma Patients
- Fatty Acid Degradation (FAD) Subtype-Informed Treatment Allocation in Unresectable Hepatocellular Carcinoma (FAD-HCC-01): Protocol for a Prospective Multicentre Proof-of-Concept Study